Gene · 6857
SYT1: synaptotagmin 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SYT1: synaptotagmin 1. Genes, record 6857. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6857
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P21579 | Synaptotagmin-1 | 422 | 24 | Ensembl, GeneID, HGNC |
Source UniProt
Patents67
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026079407 A | 2026-04-16 | 22 | P21579 | Espacenet |
| US 12560619 B2 | 2026-02-24 | 51 | P21579 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 66071 | P21579 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 66072 | P21579 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 66078 | P21579 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1438 | P21579 | Espacenet |
| JP 2025533447 A | 2025-10-07 | 28 | P21579 | Espacenet |
| WO 2025196445 A1 | 2025-09-25 | 23 | P21579 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 4552 | P21579 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 4552 | P21579 | Espacenet |
1 to 10 of 67
See all 67 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,238
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SYT1 papers | Newest fiscal year |
|---|---|---|---|
| R01MH061876 | Synaptotagmin C2B Domain as a Ca2+ Sensing Module | 67 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30DA018343 | Yale/NIDA Neuroproteomics Center | 12 | 2025 |
| R01NS080833 | Biology and Engineering of Botulinum Neurotoxins. | 11 | 2025 |
| P30DK034854 | Integrated Epithelial and Muscosal Biology | 9 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 8 | 2025 |
| P40OD018537 | Bloomington Drosophila Stock Center at Indiana University | 8 | 2025 |
| R01MH063105 | Molecular mechanisms of synaptic neurotransmitter release | 7 | 2025 |
| P30DK045735 | Yale Diabetes Research Center | 6 | 2025 |
| P30DK058404 | Molecular and Cellular Basis for Digestive Diseases | 5 | 2025 |
1 to 10 of 2,238Source NIH's project files
See all 2,238 nih grantsPapers3,871
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PAK4 exacerbates melanoma immunosuppression by promoting exosome release. | Proc Natl Acad Sci U S A | 2026 | 42826135 | PubTator, text mining | PubMed |
| A novel de novo multi-exon deletion of SYT1 in a child with Baker-Gordon syndrome. | BMC Pediatr | 2026 | 42750022 | PubTator, text mining | PubMed |
| Alternative splicing of synaptotagmin 7 regulates oligomerization and short-term synaptic plasticity. | Proc Natl Acad Sci U S A | 2026 | 42743279 | PubTator, text mining | PubMed |
| Transcriptional Profiling of Botulinum Neurotoxin Type A-Related Molecular Components in Primary Human Schwann Cells. | Toxins (Basel) | 2026 | 42646749 | PubTator, text mining | PubMed |
| Tumor-neuronal hybrid programs reveal a spatially adaptive malignant state in glioblastoma. | Front Oncol | 2026 | 42609318 | PubTator, text mining | PubMed |
| Rapid metastatic progression of primary pulmonary synovial sarcoma despite guideline-concordant multimodal therapy: a case report. | Front Oncol | 2026 | 42553211 | PubTator, text mining | PubMed |
| Electrostatics and Local Aromatic Residues Govern Lipid Binding and Membrane Penetration of Synaptotagmin C2 Domains. | bioRxiv | 2026 | 42523241 | PubTator, text mining | PubMed |
| Maternal copper levels moderate the neuroprotective effect of zinc on early childhood development: evidence from a birth cohort and proteomic profiling. | Front Nutr | 2026 | 42516235 | PubTator, text mining | PubMed |
| Higher physical activity levels mitigate synaptic protein loss and cognitive deterioration in aging and in Alzheimer's disease: a 10-year longitudinal study. | Mol Biomed | 2026 | 42455424 | PubTator, text mining | PubMed |
| Analytical and clinical validation of a novel proximity extension assay-based plasma biomarker panel in a cohort of prevalent neurodegenerative dementias. | Alzheimers Res Ther | 2026 | 42436533 | PubTator, text mining | PubMed |
1 to 10 of 3,871
See all 3,871 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6857
GET https://conductscience.org/api/genes/v1/6857/patents?page=2